A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06755347 After Single Ascending Intravenous Infusions To Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06755347 After Single Ascending Intravenous Infusions To Healthy Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs PF-06755347 (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Feb 2018 Planned End Date changed from 30 Dec 2019 to 13 Nov 2019.
    • 07 Feb 2018 Planned primary completion date changed from 30 Dec 2019 to 13 Nov 2019.
    • 26 Jan 2018 Planned End Date changed from 30 Dec 2018 to 30 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top